Related references
Note: Only part of the references are listed.Genetic and phenotypic attributes of splenic marginal zone lymphoma
Ferdinando Bonfiglio et al.
BLOOD (2022)
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
Alberto J. Arribas et al.
HAEMATOLOGICA (2022)
Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome.
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.
Erel Joffe et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Rita Alaggio et al.
LEUKEMIA (2022)
Genomic profiling for clinical decision making in lymphoid neoplasms
Laurence de Leval et al.
BLOOD (2022)
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas
Nina D. Wagner-Johnston et al.
LEUKEMIA & LYMPHOMA (2021)
MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity
Kamal U. Saikh
IMMUNOLOGIC RESEARCH (2021)
Single-Agent Ibrutinib for Rituximab-Refractory Waldenstrom Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate™ Trial
Judith Trotman et al.
CLINICAL CANCER RESEARCH (2021)
Thyroid MALT lymphoma: self-harm to gain potential T-cell help
Fangtian Wu et al.
LEUKEMIA (2021)
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
Matthew S. Davids et al.
BLOOD ADVANCES (2021)
The IRAK4 inhibitor CA-4948 demonstrates antitumor activity in a preclinical model of CNS lymphoma
Christina A. von Roemeling et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma
Panayiotis Panayiotidis et al.
BLOOD ADVANCES (2021)
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
Martin Dreyling et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma
Yun Chen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models
Eugenio Gaudio et al.
HAEMATOLOGICA (2020)
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
Constantine S. Tam et al.
BLOOD (2020)
Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma
A. Arribas et al.
EUROPEAN JOURNAL OF CANCER (2020)
Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies
Venkateshwar Rao Gummadi et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
Ariela Noy et al.
BLOOD ADVANCES (2020)
Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation
Jing Zhang et al.
CELL CHEMICAL BIOLOGY (2020)
Resistance to PI3K delta inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
Alberto J. Arribas et al.
HAEMATOLOGICA (2020)
Quantifying Drug Combination Synergy along Potency and Efficacy Axes
Christian T. Meyer et al.
CELL SYSTEMS (2019)
Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses
Luciano Cascione et al.
HAEMATOLOGICA (2019)
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Filippo Spriano et al.
CLINICAL CANCER RESEARCH (2019)
Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance
Alberto J. Arribas et al.
BLOOD (2019)
Secretion of IL16 is associated with resistance to ibrutinib in pre-clinical models of lymphoma
Alberto J. Arribas et al.
MOLECULAR CANCER THERAPEUTICS (2019)
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Chiara Tarantelli et al.
CLINICAL CANCER RESEARCH (2018)
Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma
Robert N. Booher et al.
BLOOD (2018)
Efficacy of the IRAK4 inhibitor CA-4948 in patient-derived xenograft models of diffuse large B cell lymphoma
Robert N. Booher et al.
CANCER RESEARCH (2017)
Mechanisms of Suppressive Effects of MYD88 Inhibitors on the Growth of Lymphoma and Leukemia Cells
Erika Shiratori et al.
BLOOD (2016)
Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
Priscilla N. Kelly et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response
Afua Adjeiwaa Mensah et al.
Oncotarget (2015)
MYD88 somatic mutations in MALT lymphomas
Zhi-Ming Li et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas
Qingguo Yan et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo et al.
NATURE (2011)
Genomic abnormalities acquired in the blastic transformation of splenic marginal zone B-cell lymphoma
JA Martinez-Climent et al.
LEUKEMIA & LYMPHOMA (2003)
Share Paper
